CARLSMED, INC. (CARL) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

CARLSMED, INC. (CARL) Healthcare & Pipeline Overview

Carlsmed, Inc. specializes in personalized surgical solutions for complex adult spinal deformities, integrating clinical intelligence, image recognition, and 3D printing into its aprevo platform. The company's technology aims to enhance surgical precision and patient outcomes through custom-fit devices, operating within the medical technology sector.

What Is the Investment Thesis for CARL?

Carlsmed, Inc. presents a research focus centered on its advanced surgical platform, aprevo, which addresses complex adult spinal deformities through personalized solutions. The company's approach, integrating clinical intelligence, image recognition, and 3D printing, aligns with the increasing adoption of personalized surgical methodologies, representing a key value driver. The facilitation of New Technology Add-On Payment (NTAP) reimbursement further supports market access and adoption for its innovative devices. With a market capitalization of $299M and a robust gross margin of 75.9%, Carlsmed demonstrates strong operational efficiency at the product level. However, a profit margin of -58.8% indicates significant operating expenses relative to revenue, necessitating careful monitoring of the company's ability to manage costs as it scales production and gains market share. The high beta of 1.97 suggests higher volatility relative to the broader market. The primary growth catalysts include continued market penetration of its personalized aprevo system and the broader industry shift towards customized patient care, while the competitive landscape of established medical device companies remains a significant risk factor.

Based on FMP financials and quantitative analysis

CARL Key Highlights

• Carlsmed, Inc. maintains a strong Gross Margin of 75.9%, indicating efficient cost management relative to its revenue from product sales.
• The company's Market Capitalization stands at $0.31 billion, reflecting its current valuation within the specialized medical technology sector.
• A Profit Margin of -58.8% highlights the company's current stage of investment in growth and scaling, with operating expenses exceeding revenues.
• Carlsmed's Beta of 1.97 suggests higher volatility compared to the overall market, which is common for growth-oriented medical technology companies.
• The company's core offering, the aprevo interbody system, focuses on personalized surgical solutions for complex spine conditions, leveraging advanced technologies.

Who Are CARL's Competitors?

CARL is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are CARL's Key Strengths?

• Proprietary aprevo system offers personalized surgical plans and custom-fit 3D-printed devices for complex spine conditions.
• Leverages advanced technologies including clinical intelligence, image recognition, and 3D printing.
• Facilitates New Technology Add-On Payment (NTAP) reimbursement, aiding market adoption.
• Strong gross margin of 75.9% indicates efficient production costs relative to sales.

What Are CARL's Weaknesses?

• Currently operates with a significant negative profit margin of -58.8%, indicating high operating expenses.
• Relatively small market capitalization of $299M compared to established medical device companies.
• Challenges in scaling production and managing operating expenses as the company grows.
• High beta of 1.97 suggests increased stock price volatility.

What Could Drive CARL Stock Higher?

• Increasing adoption of personalized surgical approaches in spine care, driven by demonstrated clinical benefits and surgeon preference for tailored solutions.
• Potential market share gains for the aprevo system as more healthcare providers recognize the value of personalized 3D-printed interbody devices for complex spinal deformities.
• Continued facilitation of New Technology Add-On Payment (NTAP) reimbursement, which lowers financial barriers for hospitals and encourages the integration of Carlsmed's innovative technology.
• Publication of additional clinical data and real-world evidence demonstrating superior patient outcomes and cost-effectiveness of the aprevo system, further accelerating adoption.

What Are the Key Risks for CARL?

• Negative return on equity (-61.8%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Intense competitive landscape with established medical device companies that possess greater resources and market penetration in the spine surgery sector.
• Challenges in effectively managing operating expenses as the company scales its production and expands its market presence, impacting its path to profitability.
• Market acceptance and adoption rates of new personalized surgical technologies may be slower than anticipated due to ingrained practices or perceived complexities.
• Sustaining and improving profitability given the current -58.8% profit margin will require significant revenue growth and cost control measures.
• Dependence on the continued availability and favorable terms of New Technology Add-On Payment (NTAP) reimbursement for market access and adoption.

What Are the Growth Opportunities for CARL?

• **Expanding Adoption of Personalized Surgical Approaches:** The healthcare industry is increasingly moving towards personalized medicine, recognizing that individual patient anatomies and pathologies require tailored solutions for optimal outcomes. Carlsmed's aprevo system is at the forefront of this trend in spine surgery, offering custom-fit devices and personalized surgical plans. As clinical evidence mounts and awareness grows among surgeons and healthcare systems regarding the benefits of personalized approaches—such as reduced complications, improved functional recovery, and enhanced patient satisfaction—Carlsmed stands to capture a larger share of this evolving market. This shift represents a significant long-term growth driver, with the potential for widespread adoption across various complex spinal conditions.
• **Leveraging New Technology Add-On Payment (NTAP) Reimbursement:** The facilitation of New Technology Add-On Payment (NTAP) reimbursement is a critical strategic advantage for Carlsmed. NTAP is designed to support the adoption of new medical technologies that represent a substantial clinical improvement over existing options, by providing additional reimbursement to hospitals. This mechanism helps mitigate the financial barriers that often hinder the integration of innovative, but potentially more costly, technologies into routine clinical practice. By ensuring that hospitals can be adequately compensated for using the aprevo system, Carlsmed significantly enhances its market access and attractiveness to healthcare providers, accelerating the system's penetration into the complex spine surgery market.
• **Market Share Expansion in Complex Spine Surgery:** Despite the presence of established medical device companies, Carlsmed's unique personalized approach offers a compelling differentiation point. The company has the opportunity to gain significant market share by demonstrating superior clinical outcomes, enhanced surgical precision, and improved patient-specific results compared to traditional, off-the-shelf solutions. Focusing on robust clinical data, surgeon education, and strategic partnerships with leading spine centers can drive adoption. As the aprevo system proves its value in addressing the most challenging adult spinal deformities, its reputation and market presence can expand, attracting more surgeons and patients seeking advanced, tailored treatment options.
• **Technological Advancements and Platform Expansion:** Carlsmed's foundation in clinical intelligence, image recognition, and 3D printing provides a robust platform for future technological advancements. There is a substantial opportunity to expand the capabilities of the aprevo system, potentially incorporating more advanced AI algorithms for predictive modeling, integrating new biocompatible materials for 3D printing, or extending the platform's application to other orthopedic or surgical specialties. Continuous innovation in these areas can strengthen the company's competitive moat, attract new talent, and open up new revenue streams by addressing a broader range of complex medical conditions beyond its current focus on adult spinal deformities, ensuring long-term relevance and growth.
• **Strategic Partnerships and Clinical Evidence Generation:** Building strong strategic partnerships with key opinion leaders, academic medical centers, and large hospital systems is crucial for Carlsmed's growth. These collaborations can facilitate the generation of high-quality clinical evidence, including prospective studies and real-world data, which are essential for driving widespread adoption and securing favorable reimbursement policies. Demonstrating the long-term efficacy, safety, and cost-effectiveness of the aprevo system through rigorous clinical research will be paramount. Such evidence not only validates the technology but also builds trust within the surgical community, accelerating market acceptance and solidifying Carlsmed's position as a leader in personalized spine care.

What Opportunities Does CARL Have?

• Increasing adoption of personalized surgical approaches in the broader healthcare market.
• Potential to gain market share by demonstrating superior outcomes for complex spinal deformities.
• Expansion of the aprevo system's application or development of complementary personalized solutions.
• Strategic partnerships to accelerate market penetration and clinical evidence generation.

What Threats Does CARL Face?

• Intense competitive landscape dominated by established medical device companies in the spine surgery market.
• Ongoing need to manage operating expenses effectively to move towards profitability.
• Potential for slower-than-anticipated market adoption of new personalized surgical technologies.
• Regulatory hurdles and reimbursement policy changes inherent in the medical device industry.

What Are CARL's Competitive Advantages?

• Proprietary advanced surgical platform integrating clinical intelligence, image recognition, and 3D printing for personalized solutions.
• Unique aprevo medical system offering custom-fit devices and surgical plans tailored to individual patient anatomy.
• Strategic advantage through the facilitation of New Technology Add-On Payment (NTAP) reimbursement, aiding market adoption.
• Specialized focus on complex adult spinal deformities, allowing for deep expertise and targeted innovation in a niche market.

What Does CARL Do?

Carlsmed, Inc., established in 2018 and headquartered in Carlsbad, California, operates an advanced surgical platform specifically engineered to address intricate adult spinal deformities. The company's core mission revolves around empowering surgeons with cutting-edge tools that integrate clinical intelligence, sophisticated image recognition, and advanced 3D printing technologies. At the heart of its offering is the aprevo medical system, a proprietary solution dedicated to crafting highly personalized surgical plans and custom-fit devices. These devices are precisely matched to each individual patient's unique anatomical and medical profile, moving beyond traditional, one-size-fits-all approaches in spine surgery. This personalized methodology is designed to optimize surgical outcomes and enhance patient recovery. Furthermore, Carlsmed, Inc. plays a crucial role in facilitating New Technology Add-On Payment (NTAP) reimbursement, which is vital for the adoption of innovative medical technologies by healthcare providers. The company's focus on enabling technologies for personalized spine conditions positions it within a specialized and evolving segment of the medical device industry, aiming to improve the standard of care for complex spinal conditions through precision and customization.

What Products and Services Does CARL Offer?

• Designs and manufactures personalized surgical solutions for complex adult spinal deformities.
• Operates an advanced surgical platform integrating clinical intelligence and sophisticated image recognition.
• Utilizes cutting-edge 3D printing technologies to create custom-fit medical devices.
• Offers its key product, the aprevo medical system, for personalized surgical planning.
• Develops custom-fit devices precisely matched to individual patient profiles.
• Facilitates New Technology Add-On Payment (NTAP) reimbursement for its innovative solutions.
• Aims to empower surgeons with tools for enhanced precision and patient outcomes in spine surgery.

How Does CARL Make Money?

• Generates revenue through the sale of its personalized surgical plans and custom-fit devices, primarily the aprevo interbody system.
• Benefits from the adoption of its technology, which is supported by the company's role in facilitating New Technology Add-On Payment (NTAP) reimbursement.
• Focuses on a high-value, specialized market segment addressing intricate adult spinal deformities, commanding premium pricing for its customized solutions.

What Industry Does CARL Operate In?

Carlsmed, Inc. operates within the specialized segment of the Medical - Healthcare Information Services industry, specifically targeting complex adult spinal deformities. The broader medical device market is experiencing a significant trend towards personalized medicine, where treatments and devices are tailored to individual patient needs. Carlsmed's aprevo system, which utilizes clinical intelligence, image recognition, and 3D printing for custom-fit devices, positions it directly within this growing niche. The competitive landscape is characterized by established medical device companies that have long dominated the spine surgery market with standardized implants and surgical tools. Carlsmed differentiates itself by offering a highly customized approach, aiming to improve surgical precision and patient outcomes. The company's ability to leverage New Technology Add-On Payment (NTAP) reimbursement further underscores its innovative positioning, providing a pathway for adoption in a market that values advanced, patient-specific solutions.

Who Are CARL's Key Customers?

• Spine surgeons seeking advanced, personalized tools for complex adult spinal deformity correction.
• Hospitals and surgical centers aiming to offer cutting-edge, patient-specific treatments and improve surgical outcomes.
• Patients diagnosed with intricate adult spinal deformities who require customized surgical solutions.

Company Profile

CARLSMED, INC. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Carlsbad, US. The company is led by CEO Michael Cordonnier. CARL has traded publicly since 2025.

F-Score 3/9Financial Health

CARLSMED, INC.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 6.20 places it in the safe zone, indicating low near-term bankruptcy risk.

ROE -62%Key Financial Metrics

Return on equity for CARLSMED, INC. stands at -61.8%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -27.9%, showing how much profit it generates from its asset base. Its free cash flow yield is -12.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 11.88 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -11.9%, the inverse of the P/E and a quick read on earnings relative to price.

CARL Valuation & Market Position

With a $299M market cap, CARLSMED, INC. sits in the micro-cap segment of the market. Relative to its peer group, CARL's quantitative score of 29/100 is below the peer average of 66/100.

FY2026 estForward Outlook

Wall Street analysts project CARLSMED, INC. revenue of about $74.8M for fiscal 2026, with EPS near $-1.48. The estimate reflects 3 contributing analysts.

CARL Financials

CARL Latest News

CARL Analyst Consensus

CARL MoonshotScore

CARL Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources